Surgical Science (Q3 review): Soft margins and cash conversion - Redeye

Redeye updates its estimates following Surgical Science’s Q3 2025 report, which featured decent sales but subpar profitability and cash flows. While we believe the share’s valuation has become undemanding, recent performance throws into doubt whether the company can reach its margin target for 2026e.

Länk till analysen i sin helhet: https://www.redeye.se/research/1138920/surgical-science-q3-review-soft-margins-and-cash-conversion?utm_source=finwire&utm_medium=RSS